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Abstract
Background—In the United States, clade B is the predominant human immunodeficiency virus
(HIV) subtype, whereas in sub-Saharan Africa, clades A, C, and D are the predominant subtypes.
HIV subtype may have an impact on HIV disease progression. The effect of HIV subtype on the risk
of dementia has, to our knowledge, not been examined. The objective of this study was to examine
the relationship between HIV subtype and the severity of HIV-associated cognitive impairment
among individuals initiating antiretroviral therapy in Uganda.
Methods—Sixty antiretroviral-naive HIV-infected individuals with advanced immunosuppression
who were at risk of HIV-associated cognitive impairment underwent neurological,
neuropsychological, and functional assessments, and gag and gp41 regions were subtyped. Subtype
assignments were generated by sequence analysis using a portion of the gag and gp41 regions.
Results—Thirty-three HIV-infected individuals were infected with subtype A, 2 with subtype C,
9 with subtype D, and 16 with A/D recombinants. Eight (89%) of 9 HIV-infected individuals with
subtype D had dementia, compared with 7 (24%) of 33 HIV-infected individuals with subtype A
(P = .004).
Conclusions—These results suggest that, in untreated HIV-infected individuals with advanced
immunosuppression who are at risk of developing HIV-associated cognitive impairment, HIV
dementia may be more common among patients infected with subtype D virus than among those
infected with subtype A virus. These findings provide the first evidence, to our knowledge, to
demonstrate that HIV subtypes may have a pathogenetic factor with respect to their capacity to cause
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cognitive impairment. Additional studies are needed to confirm this observation and to define the
mechanism by which subtype D leads to an increased risk of neuropathogenesis.
Human immunodeficiency virus (HIV)–associated neurocognitive disorders (HANDs) are
characterized by disabling cognitive, behavioral, and motor dysfunction and are a common
neurological manifestation of advanced HIV infection. The prevalence of HIV-associated
dementia, the most severe form of HAND, in resource-limited settings such as countries in
sub-Saharan Africa is largely unknown, but a recent study suggests that the prevalence in
Uganda may be as high as 31% [1].
HIV type 1 (HIV-1) is characterized by extensive genetic diversity and can be divided into 3
classes: group M (major), group O (outlier), and group N (new, non-M, and non-O). Group M
is responsible for >90% of cases of HIV infection globally and is represented by 9 major
subtypes or clades (A–D, F–H, J, and K) [2]. The HIV-1 subtypes in the United States differ
from the subtypes seen elsewhere in the world. In the United States, clade B is the predominant
subtype, whereas in sub-Saharan Africa, clades A, C, and D are the predominant subtypes
[2].
HIV subtype has an impact on HIV disease progression. Studies from Uganda, Kenya, and
Tanzania have demonstrated that HIV-infected individuals infected with subtype D virus have
a faster progression to AIDS and a higher mortality rate than do HIV-infected individuals
infected with subtype A virus [3–6]. These data demonstrate a virus-specific component, which
is subtype specific and impacts virulence. The effect of HIV subtype on the risk of HIV
dementia has, to our knowledge, not been examined in well-characterized HIV-infected
individuals in Africa. The objective of this study was to characterize the HIV subtype among
HIV-infected individuals initiating highly active antiretroviral therapy (HAART) in Uganda




The study enrolled 60 antiretroviral-naive HIV-infected individuals from a larger project
evaluating the effect of HAART on HIV-infected individuals who were at risk of developing
cognitive impairment at an infectious diseases clinic in Kampala, Uganda, from September
2005 through January 2007 [7]. HIV-infected individuals were chosen to receive HAART
using the following inclusion criteria: advanced HIV infection, with a CD4 lymphocyte count
<200 cells/μL; attendance of at least 2 clinic visits in the prior 6 months; residence within a
20-km radius of Kampala; performance on a screening test for HIV dementia (International
HIV Dementia Scale [IHDS], ≤10) suggestive of HAND [8]; and provision of written informed
consent. Exclusion criteria included age <18 years, an active or known past opportunistic
infection of the central nervous system, fever (temperature, >37.5°C), and a history of a chronic
neurologic disorder, active psychiatric disorder, alcoholism, physical deficit (eg, amputation),
severe functional impairment (Karnofsky performance scale, <50) [9], or severe medical illness
that would interfere with the ability to perform the study evaluations. The evaluations were
translated into the local language, Luganda.
Clinical assessments
HIV-infected individuals received standardized questionnaires for assessment of demographic
information and medical, psychiatric, and neurologic history and underwent a neurologic
examination [1], including assessments of cranial nerves, limb strength and coordination, limb
vibration and pin sensation, gait, and deep tendon reflexes in all extremities [1]; patients were
also evaluated for fever, headache, neck stiffness, and focal abnormalities. HIV-infected
Sacktor et al. Page 2













patients with suspected opportunistic infection of the central nervous system or neoplasm were
excluded from the study.
The neurocognitive assessment included a screening test for HIV dementia, the IHDS [8], and
a full neuropsychological test battery. Participants were antiretroviral naive prior to the
neurocognitive assessment. The IHDS consists of 3 subtests (timed finger tapping, a timed
alternating hand sequence test, and recall of 4 items at 2 min) and has been validated as a
sensitive screening test for HIV dementia in Uganda [8]. The neuropsychological testing
battery included the World Health Organization–University of California–Los Angeles
Auditory Verbal Learning test for verbal memory [10], the Timed Gait and Grooved Pegboard
Tests to assess motor performance, the Symbol Digit Test [11] and Color Trails Test [10] to
assess psychomotor speed performance, the Digit Span Forward and Backward to assess
attention, the finger tapping test to assess motor performance, and the category naming test to
assess verbal fluency. The functional assessment included the Karnofsky performance scale
[9]. These assessments were used to assign a Memorial Sloan Kettering (MSK) dementia stage
of 0 (normal neurocognitive function), 0.5 (equivocal symptoms or signs without impairment
in capacity to perform activities of daily living), or ≥1 (HIV dementia; ie, abnormal
neuropsychological test findings and mild-to-moderate functional impairment) [12]. A
diagnosis of HIV dementia required impairment in ≥2 neuropsychological tests in which the
subject scored <1.5 standard deviations below the locally determined mean for his or her
normative age and education group and had symptomatic and/or functional complaints
consistent with dementia or findings from a neurologic examination consistent with HIV
dementia (eg, extrapyramidal signs) [1].
CD4 lymphocyte counts and plasma HIV loads were determined for all HIV-infected subjects
on the same day as the neurocognitive assessment. Analysis of cerebrospinal fluid specimens
and neuroimaging were not performed in this study.
RNA extraction and amplification of gag and gp41 fragments
Viral RNA was extracted from 140 μL of serum using QlAmp Viral RNA Mini Kit (Qiagen)
with the modifications listed below. The final elution was performed with 50 μL of deionized
diethylpyrocarbonate–treated water into a tube that contained 1 μL of 100 U of RNAse inhibitor
(RNAsin; Promega). The eluted RNA was used for reverse-transcription polymerase chain
reaction in 2 separate reactions with HIV-1–specific primers in the gag and gp41 env regions.
Information about the primer sequences and amplification protocols have been described in
detail elsewhere [13,14].
The purified nested polymerase chain reaction products from the gag and gp41 regions were
used for automated sequencing with a BigDye terminator cycle-sequencing ready reaction kit.
The sequencing reactions were then run in a 377 DNA sequencer (PE Applied Biosystems).
These sequences, along with reference sequences from the HIV sequence database, were
aligned using the CLUSTALW multiple-sequence alignment program [15] and were optimized
by hand using BIOEdit, version 5.09 [16].
Phylogenetic analysis and subtype assignment
Phylogenetic trees were generated using Nimble Tree
(http://sray.med.som.jhmi.edu/SCRoftware/), which incorporates PHYLIP, version 3.572c
[15]. DNADIST was used to calculate the genetic distance matrix using a maximum likelihood
model with a transition-to-transversion ratio of 2.0 [17]. Trees were generated from the distance
matrix using the neighbor-joining algorithm in NEIGHBOR [15]. Bootstrap confidence
intervals were calculated by randomly permuting the sequence alignment 100 times with
SEQBOOT [15]. Consensus topology was derived by the use of CONSENSE [16]. Bootstrap
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values >75% were considered significant. Nucleotide positions in relation to HXB2 were
determined using the HIV numbering engine and reference sequences for different HIV-1
group M subtypes obtained from Los Alamos (http://web.lanl.gov/seq-db.html). Reference
sequences used included fragments of the full-length sequences previously generated from this
region (accession numbers AF-484502 to AF-484520 and HXB2 (accession number K03455).
Sequence subtype classification for both the gag and gp41 fragments was based on their relation
to the closest reference sequence. The reference sequences (accession numbers) that were used
were A1 (U51190), A2 (AF286238), B (K03455), C (U46016), D (U88824), F1 (AJ249238),
F2 (AJ249237), G (U88826), H (AF005496), J (AF082394), and K (AJ249239). The sequence
analysis was based on a portion of the gp41 (HXB2 nucleotide [nt] 7867–8283) and gag (HXB2
nt 1240–1907) regions. Sequences generated for this study have been submitted to GenBank
(accession numbers EU841418–EU841480 and EU850290–EU850351). Subjects were
considered infected with a specific subtype if both regions analyzed were from the same
subtype. If there was a discordance between the gag and gp41 subtype assignments, the subject
was considered to be infected with a recombinant strain. Subtype assignments were confirmed
by using the Web-based REGA subtyping tool (http://www.bioafrica.net/subtypetool/html).
Sequence fragments that demonstrated any evidence of incorporating a recombinant breakpoint
based on their position on the tree or from the REGA subtyping tool were further analyzed
using SimPlot [18]. Potential break points were confirmed by generating a phylogenetic tree
on each portion on both sides of the putative break point. If the 2 portions clustered significantly
to 2 different subtypes, the sequence fragment was considered to have incorporated a
recombination break point.
Data analysis
For each neuropsychological test, a Z score was calculated using age- and education-adjusted
normative data obtained from 100 HIV-uninfected individuals in Uganda [1]. Distributional
tests have confirmed that the resultant Z scores follow a normal distribution, and scores are
summarized as mean ± standard deviation. Baseline differences in demographics were
examined using the t test and the χ2 test among HIV-infected individuals infected with subtype
A and D, the 2 predominant subtypes. A logistic regression model was used to examine for a
difference between the frequency of HIV dementia among HIV-infected individuals infected
with subtypes D and A. The association between subtype and MSK score was tested using a
χ2 test of association.
RESULTS
The demographic characteristics of the 60 HIV-infected individuals for whom subtypes of the
gp41 and gag regions were determined are summarized in Table 1, stratified by infecting HIV
subtype. There were no differences in age, education, sex, CD4 lymphocyte count, or log
plasma HIV RNA level, as stratified by infecting HIV subtype using clade assignment by
phylogenetic analysis of gag only, gp41 only, or gag and gp41. There was also no difference
in CD4 lymphocyte count or log plasma HIV RNA level among HIV-infected individuals with
and without dementia.
Analysis of the gag gene fragment
On the basis of phylogenetic analysis of the gag sequence fragment, 45 individuals were
classified as being infected with subtype A1, 2 individuals were infected with subtype C, and
20 individuals were infected with subtype D. No sequences had any evidence of recombination.
On the basis of the gag data only, there were no differences in the frequency of HIV dementia
between individuals infected with subtype A (9, 24, and 12 individuals had MSK ratings of 0,
0.5, and ≥1, respectively) and subtype D (1, 9, and 10 individuals had ratings of 0, 0.5, and ≥1,
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respectively), although we noted a trend toward a greater frequency of HIV dementia among
HIV subtype D–infected individuals (P = .15).
Analysis of the gp41 gene fragment
Forty-one individuals were classified as having subtype A infection, 2 individuals were
classified as having subtype C infection, and 20 were classified as having subtype D infection
on the basis of phylogenetic analysis of this fragment. No sequences demonstrated any evidence
of recombination. For this fragment, differences in sub-types A1 and A2 could not be inferred
and were all classified as subtype A. Individuals infected with subtype D were more likely to
have HIV dementia than were those infected with subtype A (P = .02).
HIV subtype using phylogenetic analysis of the gag and gp41 gene
There were 60 subjects who had sequence data from both the gag and gp41 regions. If the
sequence fragments had a concordant subtype for both regions, patients were considered to be
infected with that subtype. Thirty-three HIV-infected individuals were classified as being
infected with subtype A, 2 were classified as being infected with subtype C, 9 were classified
as being infected with subtype D, and 16 were classified as being infected with recombinants
with a discordant subtype assignment for gag and gp41. One-half the recombinants had a
subtype A gag and D gp41, and the other half had a subtype D gag and A gp41. As shown in
Figure 1, individuals with HIV subtype D infection had an increased frequency (89%) of HIV
dementia (MSK stage, ≥1), compared with HIV subtype A–infected individuals (24%; P = .
004). There was no difference in the frequency of HIV dementia between persons infected with
A/D recombinants and persons infected with subtype A or between persons infected with A/
D recombinants and persons infected with subtype D. HIV subtype D–infected individuals had
more-impaired digit span forward performance, compared with HIV subtype A–infected
individuals (P = .04) (Table 2). There were no differences between HIV subtype D–infected
and HIV subtype A–infected individuals in any of the other individual neuropsychological
tests.
DISCUSSION
The results of our study suggest that, among HIV-infected individuals with advanced
immunosuppression at risk of developing cognitive impairment, HIV dementia is more
common among subtype D–infected persons than among subtype A–infected persons, as
determined by phylogenetic analysis of both the gag and gp41 regions. These findings provide,
to our knowledge, the first direct evidence in well-characterized HIV-infected individuals at a
similar stage of HIV disease that HIV subtypes may have a different biological impact on
neurological complications of HIV infection—namely, HAND. These results are consistent
with previous data suggesting that HIV subtype D may be associated with more-rapid HIV
disease progression—specifically, a lower CD4 cell count during follow-up and a faster
progression to death—compared with subtype A. In a study of 140 HIV-infected seroconverters
in Rakai, Uganda, 59% of subtype D–infected subjects experienced progression to AIDS or
died, whereas 29% of subtype A–infected subjects experienced progression to AIDS, and none
died [3]. Similar results were seen in another study of 1045 HIV-infected individuals in Uganda
in which subtype D infection was associated with a lower CD4 cell count during follow-up
and a faster progression to death [4]. Also, in a study from Senegal, the incidence of AIDS was
14.5 cases per 100 person-years for subtype D–infected individuals, 16.0 cases per 100 person-
years for subtype C–infected individuals, and 3.5 cases per 100 person-years for subtype A–
infected individuals [2,20]. Another study of 428 HIV-infected women in Tanzania also found
that subtype D–infected individuals experienced more-rapid progression to a CD4 cell count
≤200 cells/μL and World Health Organization stage 4 illness and a higher mortality rate,
compared with subtype A–infected individuals [2,5]. These data suggest that HIV subtypes
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may differ with respect to virulence and the risk of HIV-associated complications from
advanced immunodeficiency.
A limitation to the study is that HIV-infected individuals at risk of developing cognitive
impairment were involved in the study. They had abnormal performances on a screening test
for HIV dementia (IHDS, ≤10), suggestive of HAND, and CD4 lymphocyte counts <200 cells/
μL. However, dementia is primarily observed in patients with advanced immunosuppression
(CD4 lymphocyte count, <200 cells/μL). In addition, our subtype distribution for the subjects
studied in Kampala is remarkably similar to the subtype distribution of the polymerase gene
among 279 women who attended a prenatal clinic in Kampala (subtype A, 53%; subtype D,
35%; subtype C, 2%; and recombinants, 10%) [21]. Nevertheless, the finding that 89% of
subjects infected with subtype D had evidence of dementia, compared to 24% of those infected
with subtype A, suggests that subtype D is associated with an increased risk of dementia.
Additional studies need to be performed to determine whether the risk of HIV dementia is
increased for subtype D versus subtype A among all HIV-infected individuals in Uganda.
One hypothesis for this differential rate of progression for HIV subtypes relates to differences
in coreceptor use. HIV subtype A and subtype C favor the chemokine receptor CCR5 for viral
entry throughout the course of infection [2,22]. The use of CCR5 receptors seen in subtype A
and C correlates with a nonsyncytium inducing macrophage-tropic version of HIV, which is
associated with slower viral growth and replication [2,22,23]. In contrast, HIV subtype D
displays a tropism for the syncytium-inducing chemokine receptor observed principally in T
cells [2,23] and possibly a dual tropism for both coreceptors [2,5,24]. CXCR4 T cell tropic
strains are associated with more-rapid viral growth and replication, which could allow subtype
D to infect more cells per unit of time than other subtypes, allowing for more-rapid HIV disease
progression [2,5].
With respect to potential mechanisms for a differential rate of neurovirulence by subtype, one
possible mechanism relates to the tat gene. Recent data suggest that the tat gene in subtype C
is associated with increased cell survival in rat hippocampal neuron cultures, compared with
in subtype B [25], but the relative neurotoxicity of other clades, such as A and D, requires
further study. The neurotoxicity of tat may occur through binding of the NMDA receptor,
allowing for calcium-induced excitotoxicity, increased apoptosis, neuronal injury, and death.
Another possible mechanism for an increased risk of neuro-pathogenesis from subtype D
relates to differences in the V3 loop of the envelope gene [2,26–29]. The hypervariable V3
loop of the envelope glycoprotein gp120 is involved in HIV entry into the CD4 cell, and clade
D strains have been identified with a more-variable pattern of V3 loop amino acids than other
subtypes [2,27,30]. Viral envelope diversity can influence the progression of neurological
disease in several other retroviruses [2,31,32], and similar effects may be seen with the HIV
envelope gene [2]. HIV dementia–associated strains differ predominantly in the V1 and V3
region of the gp120 envelope protein, which are the same regions that account for HIV subtype
diversity [2,28,29,32,33]. Of note, in the phylogenetic analyses for subtype determination in
this study, subtype D was associated with an increased risk of HIV dementia in the gp41
envelope gene, whereas only a trend was seen for an increased association of subtype D for
HIV dementia in the gag gene. These results suggest that the envelope gene may be more
critical for conferring an increased risk of HIV dementia than is the gag gene in subtype D–
infected individuals. Differences in coreceptor use and syncytium inducibility as described
above could also account for differences in neurovirulence.
The genetic diversity of the HIV virus is due to many factors, including its high replication
rates, lack of a proofreading capacity with mismatch errors, and a propensity for recombination
[2,34,35]. The HIV virus has more genetic diversity and interclade recombination occurs more
frequently in Africa than in the United States [2,36]. Thus, Africa is an ideal setting to examine
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issues related to subtype and the risk of HIV dementia. In Uganda, where 2 HIV subtypes
predominate, our results suggest that subtype D is associated with an increased risk of HIV
dementia. Additional studies are needed to confirm this observation. The precise mechanism
by which subtype D leads to an increased risk of HIV dementia remains to be elucidated, but
differences in the tat gene, envelope gene, coreceptor use, and syncytium inducibility may be
involved. Additional studies are needed globally to define the frequency of HIV dementia in
all subtypes and to define the rate of progression of HAND within specific HIV subtypes. The
effect of HIV subtype on other neurological complications of HIV infection, such as sensory
neuropathy and opportunistic infection of the central nervous system, also should be examined.
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Frequency of human immunodeficiency virus (HIV)–associated cognitive impairment among
antiretroviral-naive individuals in Uganda infected with HIV subtype A (n = 33), C (n = 2), D
(n = 9), and A/ D recombinant (n = 16). HIV dementia stage was defined using the Memorial
Sloan Kettering (MSK) stages of 0 (normal; ie, normal neurocognitive function), 0.5 (equivocal
or subclinical; ie, equivocal symptoms or signs without impairment in capacity to perform
activities of daily living; equivalent to asymptomatic neurocognitive impairment or mild
neurocognitive disorder [19]), and ≥1 (HIV dementia; ie, unequivocal evidence [symptoms or
signs including performance on neuropsychological tests] and mild-moderate functional
impairment) [12].
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Table 1
Demographic Characteristics of Human Immunodeficiency Virus (HlV)–Infected Individuals, Stratified by HIV
Subtype
HIV subtype
Characteristic A C D A/D recombinant
Patients for whom the gag gene fragment was analyzed
    No. of patients 45 2 20
    Age, years 34.0 ± 0.9 37.0 ± 5.0 33.5 ± 1.2 ...
    Education, years 9.0 ± 0.7 13.0 ± 0.0 10.5 ± 0.9 ...
    Percentage of male subjects 27 50 30 ...
    CD4 lymphocyte count, cells/μL 105.0 ± 10.8 51.0 ± 5.0 108.5 ± 14.7 ...
    Log plasma HIV RNA level, copies/mL 5.3 ± 0.1 5.2 ± 0.6 5.2 ± 0.2 ...
Patients for whom the gp41 gene fragment was analyzed
    No. of patients 41 2 20 ...
    Age, years 33.0 ± 0.9 37.0 ± 5.0 35.5 ± 1.4 ...
    Education, years 8.0 ± 0.8 13.0 ± 0.0 9.5 ± 0.9 ...
    Percentage of male subjects 27 50 35 ...
    CD4 lymphocyte count, cells/μL 105.0 ± 11.3 51.0 ± 5.0 95.5 ± 17.9 ...
    Log plasma HIV RNA level, copies/mL 5.3 ± 0.1 5.2 ± 0.6 5.2 ± 0.2 ...
Patients for whom the gag and gp41 gene fragments were analyzed
    No. of patients 33 2 9 16
    Age, years 34.0 ± 1.0 37.0 ± 5.0 35.0 ± 1.9 32.5 ± 1.5
    Education, years 8.0 ± 0.8 13.0 ± 0.0 10.0 ± 0.9 10.0 ± 1.2
    Percentage of male subjects 27 50 44 18
    CD4 lymphocyte count, cells/μL 90.0 ± 12.6 51.0 ± 5.0 66.0 ± 18.5 148.0 ± 18.4
    Log plasma HIV RNA level, copies/mL 5.3 ± 0.2 5.2 ± 0.6 5.1 ± 0.3 5.3 ± 0.2
NOTE. Data are median ± standard error, unless otherwise indicated.













Sacktor et al. Page 12
Table 2
Neuropsychological Test Differences Stratified by Subtype Using Analysis of gag and gp41 Genes
Median score ± standard error, by HIV subtype
Test A (n = 33) C (n = 2) D (n = 9) A/D recombinant (n = 16)
WHO UCLA AVLT trial 5 38.0 ± 1.2 39.5 ± 10.0 35.0 ± 1.8 36.5 ± 1.6
Timed Gait 9.0 ± 0.4 9.0 ± 0.4 9.7 ± 0.6 8.2 ± 0.3
Grooved Pegboard Test
    Dominant hand 85.0 ± 4.2 146.5 ± 79.5 98.0 ± 11.1 72.0 ± 5.4
    Nondominant hand 102.0 ± 13.7 158.5 ± 77.5 121.0 ± 12.5 100.0 ± 6.3
Symbol Digit Modalities Test 23.0 ± 1.7 31.0 ± 4.0 20.0 ± 2.6 20.5 ± 2.2
Color Trails Test
    Part 1 94.0 ± 11.0 75.5 ± 12.5 125.0 ± 12.8 88.0 ± 10.8
    Part 2 180.0 ± 16.4 270.5 ± 116.5 215.0 ± 24.7 174.0 ± 21.5
Digit Span
    Forward 6.0 ± 0.2 5.5 ± 0.5 5.0 ± 0.2a 5.0 ± 0.2
    Backward 3.0 ± 0.1 3.5 ± 0.5 3.0 ± 0.3 3.0 ± 0.2
Finger tapping test
    Dominant hand 165.0 ± 7.3 181.0 ± 21.0 163.0 ± 15.8 200.0 ± 12.0
    Nondominant hand 172.0 ± 8.8 NA 192.5 ± 37.5 170.5 ± 10.0
Category naming 13.0 ± 0.8 15.0 ± 4.0 12.0 ± 1.1 13.0 ± 0.5
NOTE. NA, not available; WHO UCLA AVLT, World Health Organization–University of California-Los Angeles Auditory Verbal Learning test.
a
P = .04 for subtype D vs subtype A.
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